Pfizer reported on Friday that its vaccine was 90.7 p.c efficient in stopping symptomatic Covid-19 in kids ages 5 to 11, in accordance with medical trial knowledge.
The corporate submitted the information to the Meals and Drug Administration, which was anticipated to launch its personal evaluation of the info later within the day.
Youngsters within the trial obtained a dose of 10 micrograms, smaller than the 30-microgram dose given to adults. The corporate stated that the dosage was secure, and that trial contributors had seen solely delicate unwanted side effects.
Of two,268 kids within the trial, twice as many got the vaccine as obtained a placebo. Sixteen kids who obtained the placebo received Covid-19, in contrast with three who obtained the vaccine, a outcome that interprets to greater than 90 p.c efficacy.
The corporate launched the info earlier than a gathering subsequent week at which skilled advisers to the F.D.A. will determine whether or not to advocate that the company authorize the vaccine for youngsters on this age group. Federal regulators have already made the vaccine obtainable for these 12 and older.
If the F.D.A. authorizes the vaccine for ages 5 to 11 — a transfer that might assist shield greater than 28 million people in the United States — the Facilities for Illness Management and Prevention will then make suggestions to the company subsequent month on how the pictures needs to be administered.
In keeping with data collated by The New York Times, 66 p.c of the U.S. inhabitants has obtained no less than one dose of a Covid vaccine, whereas 57 p.c are totally vaccinated.
https://www.nytimes.com/2021/10/22/us/politics/pfizer-vaccine-children-covid.html | Pfizer Says Its Vaccine Is Extremely Efficient in 5- to 11-12 months-Olds